Registration now open for Eyes On Cataract & Refractive 2025
Events

Registration now open for Eyes On Cataract & Refractive 2025

Virtual event offers up to 5 hours of free CME for MDs featuring rapid-fire videos, real-world case studies, and clinical expert-led interactive sessions.
Botox injections may actually help treat DED
Research

Botox injections may actually help treat DED

Botox injections significantly improved key disease parameters, supporting its potential clinical utility.
CSI Dry Eye Software releases update for AI-based clinical platform
Products

CSI Dry Eye Software releases update for AI-based clinical platform

Version 6.0 of the cloud-based software features an intuitive dashboard and automated reminders for clinicians diagnosing and treating DED patients.
Aldeyra resubmits reproxalap NDA for dry eye (again)
Pipeline

Aldeyra resubmits reproxalap NDA for dry eye (again)

Company includes new phase 3 dry eye crossover data in updated submission package; an FDA acknowledgement response is expected within 30 days.
GLP-1 drug users twice as likely to develop nAMD
Research

GLP-1 drug users twice as likely to develop nAMD

New research findings also report risk was 3 times as high among diabetic patients with the longest exposure to GLP-1 RAs.
Dry Eye Foundation to host DC advocacy days in July
Events

Dry Eye Foundation to host DC advocacy days in July

Nonprofit prepares to kick off its first-ever dry eye patient advocacy day and symposium at the Capitol to raise awareness of the impact of DED on everyday life
Glenmark launches olopatadine HCl 0.2% to US market
Products

Glenmark launches olopatadine HCl 0.2% to US market

Generic version of Alcon’s Pataday Once Daily Relief eye drops temporarily relieves itchy eyes due to pollen, ragweed, animal hair, and dander.
FDA clears Ocugen for phase 2/3 trial on Stargardt gene therapy
Pipeline

FDA clears Ocugen for phase 2/3 trial on Stargardt gene therapy

IND approval enables continued clinical evaluation of OCU410ST, a modifier gene therapy with a favorable safety and tolerability profile; plans include a 2027 BLA submission.
Study suggests toddlers’ eye movements predict their metamemory
Research

Study suggests toddlers’ eye movements predict their metamemory

Investigators demonstrate the ability to judge the reliability of our memories may develop as early as 2 years old.
FDA approves Amneal's prednisolone acetate ophthalmic suspension
Products

FDA approves Amneal's prednisolone acetate ophthalmic suspension

Referencing Allergan's Pred Forte, this 1% concentrated drop is expected to hit the U.S. market by Q3 2025.
Ocubio introduces personalized autologous serum eye drops
Products

Ocubio introduces personalized autologous serum eye drops

Based on a proprietary manufacturing protocol from Bascom Palmer, qASED uses patients’ blood in the formulation to target the ocular surface.
Study ties magnesium to reduced RVO risk
Research

Study ties magnesium to reduced RVO risk

Sufficient magnesium intake significantly reduced risk of RVO, particularly in three key subgroups.
Gore launches silicone-free syringe plunger for prefilled syringes
Products

Gore launches silicone-free syringe plunger for prefilled syringes

The 0.5 mL GORE IMPROJECT plunger is specially designed for use in various silicon-sensitive clinical applications—including IVT injections.
Qlaris Bio developing fixed-dose latanoprost and QLS-111 eye drop for glaucoma
Pipeline

Qlaris Bio developing fixed-dose latanoprost and QLS-111 eye drop for glaucoma

New combination therapy involving the prostaglandin analog targets lowering episcleral venous pressure to lower IOP.
SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform
Pipeline

SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform

Financing to support upcoming phase 3 trials on the company’s long-term delivery system of bimatoprost for glaucoma and OHT treatment.
Does silicone oil cause macular edema post-RRD surgery?
Research

Does silicone oil cause macular edema post-RRD surgery?

Study identifies two key factors that may significantly increase the risk for macular edema development.
FDA clears IND for Zhaoke Ophthalmology's CsA ophthalmic gel
Pipeline

FDA clears IND for Zhaoke Ophthalmology's CsA ophthalmic gel

Clearance paves the way for a new phase 3 trial to evaluate CsA 0.05% for its safety and efficacy among moderate-to-severe DED patients—with plans for an eventual NDA submission.
Coburn Technologies debuts the Huvitz HVS-1 Vision Screener
Products

Coburn Technologies debuts the Huvitz HVS-1 Vision Screener

Handheld portable device assesses refractive errors in just 1 second, providing non-contact and precise measurements for pediatric and elderly patients.
Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain
Products

Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain

Commercial rights for the newly-named BYQLOVI reportedly purchased from Formosa; plans include a Q4 2025 launch.
ViGeneron rebrands as VeonGen Therapeutics with new FDA designation
Pipeline

ViGeneron rebrands as VeonGen Therapeutics with new FDA designation

German-based genetic medicine company also receives a Rare Pediatric Disease Designation for its Sargardt disease gene therapy candidate.